INCY
IncyteBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The post-earnings bull read is that Incyte delivered a clean quarter, kept 2026 guidance intact, showed broad commercial growth beyond Jakafi, and paired that with multiple dated regulatory and pipeline milestones. The median analyst target in the packet, $108.8095, implies moderate upside from the $97.74 anchor.
Posture
Constructive
Lead driver
Sentiment
What changed
2 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Full-year 2026 guidance was reaffirmed rather than raised, leaving less room for execution slips if the commercial mix softens.
Momentum
46
Value
66
Sentiment
66
Setup hits (3d)
2 · Net Bullish
AI TargetsBase $109.00 · Bull $120.00 · Bear $86.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-29 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $108.81
Why
Momentum46 · Δ7d -2.0
Value66 · Δ7d +0.4
Sentiment66 · Δ7d +5.5
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
46
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.0
Δ21d
+3.6
Value
66
32% active weight
Current posture
7d trendFlat
Δ7d
+0.4
Δ21d
+0.8
Sentiment
66
33% active weight
Current posture
7d trendImproving
Δ7d
+5.5
Δ21d
+13.8
Why this grade
Composite grade B. Momentum 46.2 / Value 66.3 / Sentiment 66.5
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$19.1B
Beta
0.83
Shares Out
196.32M
P/E (TTM)
17.2
P/S (TTM)
4.15
P/FCF (TTM)
16.69
Rev YoY
+20.0%
EPS YoY
+287.4%
Gross Margin
+93.5%
Op Margin
+30.8%
Net Debt
-$2.12B
Current Ratio
3.20
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology